Rare long-term survivors of pancreatic adenocarcinoma without curative resection

Table 2 Clinical characteristics of 11 non-resected ≥ 5-year survivors

Patient	Age (yr)	Gender	ECOG	BMI (kg/m2)	Pain	Weight loss	Jaundice	DM	Smoking	Biliary stent	CA19-9 (U/mL)	NLR	Tumor location	AJCC Staging	Initial therapy	Duration of initial therapy (mo)
1	52.3	Female	0	20.8	Yes	No	No	No	No	No	2183.1	2.5	Head	2	VM CRT, GD	9
2	61.6	Male	0	28	No	Yes	Yes	No	No	Yes	200	3.4	Head	3	GD, VM CRT	12
3	62.7	Female	0	24.1	Yes	Yes	No	No	Yes	No	72	1.5	Head	3	GD1, 5-FU + R1	81
4	48.3	Male	0	26.7	No	No	No	No	No	No	9.8	2.2	Head	3	VM CRT, DT	10
5	51.7	Male	0	28	No	Yes	Yes	No	No	Yes	38.8	14.2	Head	3	GD, VM CRT	4
6	66.6	Female	0	21.7	Yes	Yes	Yes	Yes	Yes	Yes	661	4.7	Head	3	VM CRT, GD	8
7	56	Female	0	24.3	Yes	Yes	Yes	No	Yes	Yes	29	1.2	Head	3	VM CRT, GD	10
8	65.4	Male	0	27.8	No	No	Yes	No	Yes	Yes	156.8	10.1	Head	2	GD1, 5-FU + R1	61
9	81	Male	0	27.8	No	Yes	No	No	Yes	Yes	19.3	7.7	Head	4	GD	12
10	72.5	Male	0	27.2	Yes	No	No	No	Yes	Yes	40	2.7	Head	3	5-FU + R	6
11	76.5	Male	0	29.1	No	No	Yes	Yes	No	Yes	594.2	6.4	Head	4	GD	12

¹Neoadjuvant therapy. NLR: Peripheral blood neutrophil-to-lymphocyte ratio; GD: Gemcitabine and doxetaxel; 5-FU + R: 5-fluorouracil and radiotherapy; VM CRT: Virginia Mason Protocol chemoradiation regimen consisting of interferon-alpha-2b.